BioCentury

8:00 AM GMT, Dec 5, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Niaspan niacin: Additional Phase III data

The double-blind, North American Phase III AIM-HIGH trial in 3,414 patients showed that high doses of daily extended-release Niaspan plus Zocor simvastatin missed the primary endpoint of significantly reducing a composite of death from

Read the full 341 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.